| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 3, Issue 9 617-625, Copyright © 1992 by American Association of Cancer Research
ARTICLES |
C Wasylyk and B Wasylyk
Centre National de la Recherche Scientifique-Laboratoire de Genetique Moleculaire des Eucaryotes/Institut National de la Sante et de la Recherche Medicale, Faculte de Medecine, Strasbourg, France.
The vEts oncoprotein and its progenitor cEts1(p68) belong to a growing family of transcription factors that are related by the conserved ets domain. We show here that the ets domain and adjacent COOH-terminal amino acids are required for DNA binding by cEts1(p68). vEts differs from cEts1(p68) in both the COOH-terminal sequence and an amino acid substitution in the ets domain. The change in the COOH-terminal sequence markedly decreases its affinity for specific DNA, and the ets domain mutation further diminishes binding. vEts does not trans-activate through the ets (PEA3) motif in vivo. Surprisingly, vEts still efficiently trans-activates the promoters of two genes, stromelysin and collagenase, that are found to be overexpressed in transformed cells. The AP1 motifs of both promoters are required for efficient activation. vEts does not bind to the AP1 motif, even in the presence of cJun and cFos. The DNA-binding domain of Ets1 is required for activation through the AP1 element. Activation is inhibited by the expression of the glucocorticoid and retinoic acid receptors, suggesting that activation by Ets does not involve reversal of negative regulators of AP1. We suggest that activation is by an indirect mechanism involving activation of endogenous genes. Our results show that vEts differs from its progenitor cEts1(p68) in its trans-activating properties. The findings suggest that activation of the Jun and Fos oncoprotein pathway is important for transformation by Ets.
This article has been cited by other articles:
![]() |
K. M. Baker, G. Wei, A. E. Schaffner, and M. C. Ostrowski Ets-2 and Components of Mammalian SWI/SNF Form a Repressor Complex That Negatively Regulates the BRCA1 Promoter J. Biol. Chem., May 9, 2003; 278(20): 17876 - 17884. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bain, M. Mendelson, and J. Sinclair Ets-2 Repressor Factor (ERF) mediates repression of the human cytomegalovirus major immediate-early promoter in undifferentiated non-permissive cells J. Gen. Virol., January 1, 2003; 84(1): 41 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Basuyaux, E. Ferreira, D. Stehelin, and G. Buttice The Ets Transcription Factors Interact with Each Other and with the c-Fos/c-Jun Complex via Distinct Protein Domains in a DNA-dependent and -independent Manner J. Biol. Chem., October 17, 1997; 272(42): 26188 - 26195. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Mattot, M. Raes, P Henriet, Y Eeckhout, D Stehelin, B Vandenbunder, and X Desbiens Expression of interstitial collagenase is restricted to skeletal tissue during mouse embryogenesis J. Cell Sci., January 2, 1995; 108(2): 529 - 535. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |